Skip to content
Triangle logo TriangleGet started
← Study library

NCT03439280 · REGISTRY CONDITION SEARCH

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2023-02-24

The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

→

outcome · POSTED

Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)

→

outcome · POSTED

Phase 1: Number of Participants With Grade 3 or Higher TEAEs

→

outcome · POSTED

Phase 1: Number of Participants With Serious TEAEs

→

outcome · POSTED

Phase 1: Number of Participants With TEAEs Leading to Treatment Discontinuation

→

outcome · POSTED

Phase 1: Number of Participants With TEAEs Leading to Dose Modifications

→

outcome · POSTED

Phase 2a: Overall Response Rate (ORR)

→

outcome · POSTED

Cmax: Maximum Observed Serum Concentration for TAK-079

→

outcome · POSTED

Tmax: Time to Reach the Maximum Observed Serum Concentration (Cmax) for TAK-079

→

outcome · POSTED

AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079

→

outcome · POSTED

Phase 1: Overall Response Rate (ORR)

→

outcome · POSTED

Percentage of Participants With Minimal Response (MR)

→

outcome · POSTED

Percentage of Participants With Positive Anti-drug Antibodies (ADA)

→

outcome · POSTED

Phase 2a: Number of Participants With DLTs

→

outcome · POSTED

Phase 2a: Number of Participants Reporting One or More TEAEs

→

outcome · POSTED

Phase 2a: Number of Participants With TEAEs Leading to Dose Modifications

→

outcome · POSTED

Phase 2a: Number of Participants With TEAEs Leading to Treatment Discontinuation

→

outcome · POSTED

Phase 2a: Duration of Response (DOR)

→

outcome · POSTED

Phase 2a: Progression Free Survival (PFS)

→

outcome · POSTED

Phase 2a: Overall Survival (OS)

→

outcome · POSTED

Phase 2a: Time to Response (TTR)

→

outcome · POSTED

Phase 1: RP2D of TAK-079

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of \<=2. 2. Has received previous myeloma-specific therapy. 3. In the Combination Cohort (TAK-079-PomDex) only must be able to take concurrent prophylactic anticoagulation per standard clinical practice as directed by the investigator and the Pomalyst product information. 4. Documentation of RRMM as defined by the International Myeloma Working Group (IMWG) criteria. 5. For Participants with MM, measurable disease defined as one of the following: * Serum M-protein \>=0.5 g/dL (\>=5 gram per liter \[g/L\]). * Urine M-protein \>=200 mg/24 hours. * In participants without measurable M-protein in serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP), a serum FLC assay result with involved FLC level \>=10 mg/dL (\>=100 milligram per liter \[mg/L\]), provided serum FLC ratio is abnormal. 6. Prior therapy should meet all the following criteria: Participants in the dose Escalation Cohort (escalation phase) and participants in the dose Confirmation Cohort; * Should be previously treated with at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a steroid. Note: Participants who have had a previous autologous stem cell transplant will have additionally been exposed to an alkylating agent; however, participant who have not had a previous autologous stem cell transplant may not have been exposed to an alkylating agent per standard practice. * Should be refractory or intolerant to at least 1 PI and at least 1 IMiD. * Should either have received \>= 3 prior lines of therapy or should have received at least 2 prior lines of therapy if one of those lines included a combination of PI and IMiD. * In phase 1, previous exposure to an anti-CD38 agent, as a single agent or in combination, is allowed but is not required. (Participants in the dose Escalation Cohort). * In phase 1 dose Confirmation Cohort, cohorts of participants that are refractory at any time to at least 1 anti-CD38 agent or who are anti-CD38 naïve will be enrolled. Participants in the Combination Cohort (TAK-079 added to PomDex cohort only): * Have undergone prior therapy with \>=2 prior anti-myeloma therapies (line of therapy defined below). * Has either relapsed or relapsed and refractory disease. Should have progressed on or within 60 days of completing the last anti-myeloma therapy (refractory defined below). 7. In the phase 2a portion of the study, up to 2 cohorts of participants with RRMM may be enrolled: 1 that is refractory to at least 1 anti-CD38 monoclonal antibody (mAb) therapy at any time during treatment and 1 that is naïve to daratumumab. Note: o Refractory is defined as at least a 25% increase in M-protein (response of stable disease during prior therapy) or PD during treatment or within 60 days after last dose of prior therapy. Exclusion Criteria: 1. Sensory or motor neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade \>=3. 2. Have received allogeneic stem cell transplant. 3. Have received anti-CD38 antibody therapy and do not fulfill a 180-day washout period before receiving TAK-079. 4. Not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade \<=1 or baseline, excluding alopecia. 5. Clinical signs of central nervous system (CNS) involvement of MM. 6. Active chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active HIV, or cytomegalovirus (CMV) infection. 7. POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome, monoclonal gammopathy of unknown significance, smoldering myeloma, solitary plasmacytoma, amyloidosis, Waldenström macroglobulinemia, or IgM myeloma. 8. Positive Coombs tests at screening. 9. For participants in the Combination Cohort (TAK-079-PomDex) only: participant has previously received pomalidomide or has hypersensitivity to thalidomide or lenalidomide.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Mezagitamab 45 mg, subcutaneously (SC), once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until progressive disease (PD), unacceptable toxicities or withdrawal due to other reasons.
    intervention Names
    1. Drug: Mezagitamab
    label
    Phase 1 Dose Escalation Cohort: Mezagitamab 45 mg
    type
    EXPERIMENTAL
  2. description
    Mezagitamab 135 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
    intervention Names
    1. Drug: Mezagitamab
    label
    Phase 1 Dose Escalation Cohort: Mezagitamab 135 mg
    type
    EXPERIMENTAL
  3. description
    Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
    intervention Names
    1. Drug: Mezagitamab
    label
    Phase 1 Dose Escalation Cohort: Mezagitamab 300 mg
    type
    EXPERIMENTAL
  4. description
    Mezagitamab 600 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
    intervention Names
    1. Drug: Mezagitamab
    label
    Phase 1 Dose Escalation Cohort: Mezagitamab 600 mg
    type
    EXPERIMENTAL
  5. description
    Mezagitamab 1200 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.
    intervention Names
    1. Drug: Mezagitamab
    label
    Phase 1 Dose Escalation Cohort: Mezagitamab 1200 mg
    type
    EXPERIMENTAL
  6. description
    Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, at product-labelled dose, orally, once daily on Days 1 to 21 and dexamethasone, at product-labelled dose, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD.
    intervention Names
    1. Drug: Mezagitamab
    2. Drug: Pomalidomide
    3. Drug: Dexamethasone
    label
    Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex
    type
    EXPERIMENTAL
  7. description
    Mezagitamab, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase was to be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study. However, Phase 2a of the study was not opened for enrollment due to changes in the Sponsor's overall clinical development plan.
    intervention Names
    1. Drug: Mezagitamab
    label
    Phase 2a: Mezagitamab
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex
    2. Phase 1 Dose Escalation Cohort: Mezagitamab 1200 mg
    3. Phase 1 Dose Escalation Cohort: Mezagitamab 135 mg
    4. Phase 1 Dose Escalation Cohort: Mezagitamab 300 mg
    5. Phase 1 Dose Escalation Cohort: Mezagitamab 45 mg
    6. Phase 1 Dose Escalation Cohort: Mezagitamab 600 mg
    7. Phase 2a: Mezagitamab
    description
    Mezagitamab subcutaneously.
    name
    Mezagitamab
    other Names
    1. TAK-079
    type
    DRUG
  2. arm Group Labels
    1. Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex
    description
    Pomalidomide orally.
    name
    Pomalidomide
    type
    DRUG
  3. arm Group Labels
    1. Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex
    description
    Dexamethasone orally.
    name
    Dexamethasone
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
50
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    TEAEs were any untoward medical occurrence (called an adverse event \[AE\]) that occurred after administration of the first dose of any study drug and through 30 days after the last dose of any study drug.
    measure
    Phase 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  2. description
    DLTs were defined as any of the following events: Grade 4 laboratory abnormalities, except those events that were clearly due to extraneous causes; nonhematologic TEAEs of grade greater than or equal to (\>=3) except grade 3 nausea/vomiting, fatigue lasting less than 72 hours, elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) that resolves to grade less than or equal to (\<=)1 or baseline within 7 days, injection reaction (IR) that responds to symptomatic treatment; Hematologic TEAEs of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade \>=4, except grade \>=3 hemolysis, grade 3 low platelet or higher count with clinically meaningful bleeding; and an incomplete recovery from treatment-related toxicity causing a greater than (\>) 2-week delay in the next scheduled injection before the initiation of Cycle 2 will be considered a DLT.
    measure
    Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)
    time Frame
    Cycle 1 (cycle length=28 days)
  3. description
    AE Grades were evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.
    measure
    Phase 1: Number of Participants With Grade 3 or Higher TEAEs
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  4. description
    TEAEs were any untoward medical occurrence (called an AE) that occurred after administration of the first dose of any study drug and through 30 days after the last dose of any study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.
    measure
    Phase 1: Number of Participants With Serious TEAEs
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  5. description
    TEAEs leading to discontinuation were any untoward medical occurrence (called an AE) that occurred after administration of the first dose of any study drug and through 30 days after the last dose of any study drug leading to discontinuation of any of the study treatment when given in combination.
    measure
    Phase 1: Number of Participants With TEAEs Leading to Treatment Discontinuation
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  6. description
    TEAEs were any untoward medical occurrence (called an AE) that occurred after administration of the first dose of any study drug and through 30 days after the last dose of any study drug. Dose modification includes dose delayed, reduced, and drug discontinued permanently. Dose reduced includes scenarios where the dose was skipped, held, or missed. Dose modifications also refer to a modification of any drug in the study treatment when given in combination.
    measure
    Phase 1: Number of Participants With TEAEs Leading to Dose Modifications
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  7. description
    ORR is defined as the percentage of participants who achieved a partial response (PR) better during the study. PR is defined as \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 milligram per (mg/) 24 hours. If serum and urine M protein are not measurable, \>= 50% decrease in difference between involved and uninvolved free light chain (FLC) levels is required in place of M protein criteria.
    measure
    Phase 2a: Overall Response Rate (ORR)
    time Frame
    Up to approximately 3.7 years
secondary Outcomes
  1. measure
    Cmax: Maximum Observed Serum Concentration for TAK-079
    time Frame
    Cycles 1 and 2: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (cycle length=28 days)
  2. measure
    Tmax: Time to Reach the Maximum Observed Serum Concentration (Cmax) for TAK-079
    time Frame
    Cycles 1 and 2: Day 1 pre-dose and at multiple time points (up to 190.95 hours) post-dose (cycle length=28 days)
  3. measure
    AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079
    time Frame
    Cycle 1 and 2: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (cycle length=28 days)
  4. description
    ORR is defined as the percentage of participants who achieved a partial response (PR) or better during the study. PR is defined as \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If the serum and urine M-protein were not measurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels was required in place of the M-protein criteria. If serum and urine M-protein were not measurable, and serum FLC was also not measurable, ≥50% reduction in bone marrow plasma cells was required in place of M-protein, provided the baseline percentage was ≥30%. In addition to the above criteria, if present at baseline, ≥50% reduction in the size of soft tissue plasmacytomas was also required. Two consecutive assessments were needed; no known evidence of progressive or new bone lesions if radiographic studies were performed. Percentages are rounded off to whole number at the nearest decimal.
    measure
    Phase 1: Overall Response Rate (ORR)
    time Frame
    Up to approximately 3.7 years
  5. description
    MR is defined as \>=25% but \<=49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50% to 89%. Percentages are rounded off to whole number at the nearest decimal.
    measure
    Percentage of Participants With Minimal Response (MR)
    time Frame
    Up to approximately 3.7 years
  6. description
    Percentages are rounded off to whole number at the nearest decimal.
    measure
    Percentage of Participants With Positive Anti-drug Antibodies (ADA)
    time Frame
    Up to approximately 3.7 years
  7. measure
    Phase 2a: Number of Participants With DLTs
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  8. measure
    Phase 2a: Number of Participants Reporting One or More TEAEs
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  9. measure
    Phase 2a: Number of Participants With TEAEs Leading to Dose Modifications
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  10. measure
    Phase 2a: Number of Participants With TEAEs Leading to Treatment Discontinuation
    time Frame
    From the first dose of study drug through 30 days after the last dose (up to approximately 3.7 years)
  11. description
    DOR is the time from date of first documentation of response to date of first documented PD. PD is increase of \>=25% from lowest response value in any of following:Serum M-protein(increase must be \>=0.5 gram per deciliter\[g/dL\];serum M component increases \>=1 g/dL are sufficient to define relapse if starting M component is \>=5 g/dL),and/or urine M-protein(increase must be \>=200 mg/24 hour), and/or only in participants without measurable serum and urine M-protein levels, difference between involved/uninvolved FLC levels (increase must be \>10 mg/dL), and only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage (percentage must be \>=10%) or definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or soft tissue plasmacytomas, and development of hypercalcemia that can be attributed solely to plasma cell proliferative disorder.
    measure
    Phase 2a: Duration of Response (DOR)
    time Frame
    Up to approximately 3.7 years
  12. description
    PFS is time from the date of the first dose until the earliest date of disease progression (PD). PD is increase of \>=25% from lowest response value in any of following: Serum M-protein (increase must be \>=0.5 g/dL; serum M component increases \>=1 g/dL are sufficient to define relapse if starting M component is \>=5 g/dL),and/or urine M-protein (increase must be \>=200 mg/24 hour), and/or only in participants without measurable serum and urine M-protein levels, difference between involved/uninvolved FLC levels (increase must be \>10 mg/dL), and only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage (percentage must be \>=10%) or definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or soft tissue plasmacytomas, and development of hypercalcemia that can be attributed solely to plasma cell proliferative disorder.
    measure
    Phase 2a: Progression Free Survival (PFS)
    time Frame
    Up to approximately 3.7 years
Full study description
brief Summary
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.
detailed Description
The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat people who have relapsed and/or refractory multiple myeloma (RRMM). This study will assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of TAK-079 monotherapy and will provide a preliminary assessment of its activity against MM. The study is designed to consist of 2 phases: Phase 1 and Phase 2a. The study could enroll approximately 100 participants. The study population of Phase 1 will consist of approximately 55 participants. Participants in Phase 1 will be assigned to TAK-079 and dose-escalation will range from 45 mg to 1800 mg. The study population of Phase 2a will consist of approximately 48 participants. Dose for Phase 2a will be based upon review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data from the preceding cohorts of Phase 1. This multi-center trial will be conducted in the United States. The overall time to participate in this study is 42 months (3.5 years). In Phase 1, participants who stop treatment for any other reason other than PD will continue to have progression-free survival (PFS) follow-up at the site every 4 weeks from the last dose of study drug up to 12 months or until PD, death, loss to follow-up, consent withdrawal or study termination. Participants will be followed 30 days after last dose of study drug or until the start of subsequent alternative anti-cancer therapy, whichever occurs first, for a follow up assessment.
Source references
references
  1. citation
    Krishnan AY, Patel KK, Mohan M, Jagannath S, Niesvizky R, Silbermann RW, Yu Z, Long T, McDonnell SRP, Berg D, Stockerl-Goldstein KE. Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma. Blood Neoplasia. 2024 Sep 18;1(4):100043. doi: 10.1016/j.bneo.2024.100043. eCollection 2024 Dec.
    pmid
    40552138
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e178eb879eba49ce3e1c
      requested nct id
      NCT03439280
      primary nct id
      NCT03439280
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      64ac5b201d2fc276439daa8b78775f10dff58f6d6aaed0024620bbe22c533636
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e178eb879eba49ce3e1c
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03439280
      occurrences
      1. context exact
        NCT03439280
        end
        11
        exact text
        NCT03439280
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/686/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5e0fc45f385885844e8cc21189705d7a9f6bbc85629c2d36e2789bfceb5f564e

    Preserved source evidence · Not medical advice